183 related articles for article (PubMed ID: 34362809)
21. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
[TBL] [Abstract][Full Text] [Related]
22. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
23. Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome.
Tang JY; Chiou AS; Mackay-Wiggan JM; Aszterbaum M; Chanana AM; Lee W; Lindgren JA; Raphael MA; Thompson BJ; Bickers DR; Epstein EH
Cancer Prev Res (Phila); 2014 Mar; 7(3):292-9. PubMed ID: 24441673
[TBL] [Abstract][Full Text] [Related]
24. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma.
Vinciullo C; Elliott T; Francis D; Gebauer K; Spelman L; Nguyen R; Weightman W; Sheridan A; Reid C; Czarnecki D; Murrell D
Br J Dermatol; 2005 Apr; 152(4):765-72. PubMed ID: 15840111
[TBL] [Abstract][Full Text] [Related]
25. High and sustained efficacy after two sessions of topical 5-aminolaevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10-year follow-up study.
Christensen E; Mørk C; Skogvoll E
Br J Dermatol; 2012 Jun; 166(6):1342-8. PubMed ID: 22309486
[TBL] [Abstract][Full Text] [Related]
26. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
[TBL] [Abstract][Full Text] [Related]
27. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma.
Eigentler TK; Kamin A; Weide BM; Breuninger H; Caroli UM; Möhrle M; Radny P; Garbe C
J Am Acad Dermatol; 2007 Oct; 57(4):616-21. PubMed ID: 17610993
[TBL] [Abstract][Full Text] [Related]
28. Treatment of cutaneous tumors with topical 5% imiquimod cream.
Alessi SS; Sanches JA; Oliveira WR; Messina MC; Pimentel ER; Festa Neto C
Clinics (Sao Paulo); 2009; 64(10):961-6. PubMed ID: 19841702
[TBL] [Abstract][Full Text] [Related]
29. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases.
Bianchi L; Orlandi A; Campione E; Angeloni C; Costanzo A; Spagnoli LG; Chimenti S
Br J Dermatol; 2004 Jul; 151(1):148-56. PubMed ID: 15270884
[TBL] [Abstract][Full Text] [Related]
30. Interventions for basal cell carcinoma of the skin.
Thomson J; Hogan S; Leonardi-Bee J; Williams HC; Bath-Hextall FJ
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD003412. PubMed ID: 33202063
[TBL] [Abstract][Full Text] [Related]
31. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
[TBL] [Abstract][Full Text] [Related]
32. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
Love WE; Bernhard JD; Bordeaux JS
Arch Dermatol; 2009 Dec; 145(12):1431-8. PubMed ID: 20026854
[TBL] [Abstract][Full Text] [Related]
33. Topical tretinoin treatment in basal cell carcinoma.
Brenner S; Wolf R; Dascalu DI
J Dermatol Surg Oncol; 1993 Mar; 19(3):264-6. PubMed ID: 8445111
[TBL] [Abstract][Full Text] [Related]
34. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial.
Peris K; Campione E; Micantonio T; Marulli GC; Fargnoli MC; Chimenti S
Dermatol Surg; 2005 Mar; 31(3):318-23. PubMed ID: 15841634
[TBL] [Abstract][Full Text] [Related]
35. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
[TBL] [Abstract][Full Text] [Related]
37. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial.
Marks R; Gebauer K; Shumack S; Amies M; Bryden J; Fox TL; Owens ML;
J Am Acad Dermatol; 2001 May; 44(5):807-13. PubMed ID: 11312429
[TBL] [Abstract][Full Text] [Related]
38. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
[TBL] [Abstract][Full Text] [Related]
39. Nonpersistence of basal cell carcinoma after diagnostic shave biopsy: reconstruction when specimen is negative during surgery.
Gurunluoglu R; Kubek E; Arton J; Olsen A; Bronsert M
Ann Plast Surg; 2015 Jun; 74(6):695-8. PubMed ID: 25969972
[TBL] [Abstract][Full Text] [Related]
40. Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma.
García-de-la-Fuente MR; Santacana M; Verdaguer J; Vilardell F; Garí E; Casanova JM
Australas J Dermatol; 2020 May; 61(2):e200-e207. PubMed ID: 31944277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
